ALBO
NASDAQAlbireo Pharma Inc.
Albireo Pharma Inc. (ALBO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for ALBO in the last 30 days. The most recent was published Feb 14, 2024.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Albireo Pharma Inc. (Amendment)SC 13G/A - ALBIREO PHARMA, INC. (0001322505) (Subject)
- 13D/GSEC Form SC 13G/A filed by Albireo Pharma Inc. (Amendment)SC 13G/A - ALBIREO PHARMA, INC. (0001322505) (Subject)
- SECSEC Form 15-12G filed by Albireo Pharma Inc.15-12G - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form EFFECT filed by Albireo Pharma Inc.EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form EFFECT filed by Albireo Pharma Inc.EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form EFFECT filed by Albireo Pharma Inc.EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form EFFECT filed by Albireo Pharma Inc.EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form EFFECT filed by Albireo Pharma Inc.EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)
- INSIDERSEC Form 4: Chiswell David closing all direct ownership in the company4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- INSIDERSEC Form 4 filed by Alesina Susan4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- INSIDERSEC Form 4 filed by Okey Stephanie4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- INSIDERSEC Form 4: Harford Simon N.R. closing all direct ownership in the company4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- INSIDERSEC Form 4: Cooper Ronald Harold Wilfred closing all direct ownership in the company4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- INSIDERSEC Form 4 filed by Streck Paul4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- INSIDERSEC Form 4: Stephenson Pamela closing all direct ownership in the company4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- INSIDERSEC Form 4: Graham Michelle closing all direct ownership in the company4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- SECSEC Form S-8 POS filed by Albireo Pharma Inc.S-8 POS - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form S-8 POS filed by Albireo Pharma Inc.S-8 POS - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form S-8 POS filed by Albireo Pharma Inc.S-8 POS - ALBIREO PHARMA, INC. (0001322505) (Filer)
- INSIDERSEC Form 4 filed by Gutch Michael4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- SECSEC Form S-8 POS filed by Albireo Pharma Inc.S-8 POS - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form S-8 POS filed by Albireo Pharma Inc.S-8 POS - ALBIREO PHARMA, INC. (0001322505) (Filer)
- SECSEC Form POS AM filed by Albireo Pharma Inc.POS AM - ALBIREO PHARMA, INC. (0001322505) (Filer)
- INSIDERSEC Form 4: Carter Martha J. decreased direct ownership by 50% to 3,654 units4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
- SECSEC Form S-8 POS filed by Albireo Pharma Inc.S-8 POS - ALBIREO PHARMA, INC. (0001322505) (Filer)
ALBO FAQ
8 questionsWhat does Albireo Pharma Inc. do?
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic...What is the latest news on ALBO?
Quantisnow has not tracked any new filings, ratings or press releases for ALBO in the last 30 days. The most recent wire item was published on February 14, 2024.Where does ALBO stock trade?
Albireo Pharma Inc. (ALBO) is listed on NASDAQ.What sector and industry is ALBO in?
Albireo Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Albireo Pharma Inc. go public?
Albireo Pharma Inc. (ALBO) completed its IPO in 2007.What are analysts saying about ALBO?
Across the last 6 analyst actions on Albireo Pharma Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Wedbush: Neutral with a $42.00 price target on 2023-01-09. Recent price targets range from $42.00 to $84.00.What companies are similar to ALBO?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare ALBO side-by-side with any of them on Quantisnow.How can I track ALBO on Quantisnow?
Quantisnow aggregates Albireo Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALBO to receive live email and push alerts on every new disclosure.